TABLE 3.
Ongoing clinical trials of adoptive immunotherapy for NPC
| Experimental regimen | Intervention model | Sample size | Clinical setting | Phase | NCT number | Estimated completion date |
|---|---|---|---|---|---|---|
| Tumor‐infiltrating lymphocytes (TILs) | Parallel, Randomized | 116 | Locoregionally advanced NPC | II | NCT02421640 | Mar 2020 |
| EBV‐specific CTL | Parallel, Randomized | 330 | Recurrent/metastatic EBV‐positive NPC | III | NCT02578641 | Jan 2023 |
| Epcam CAR‐T cells | Single Group | 30 | Recurrent/refractory NPC | I | NCT02915445 | Jul 2022 |
| LMP2 antigen‐specific TCR‐T cells | Single Group | 27 | Recurrent/metastatic NPC | I | NCT03925896 | Aug 2022 |
| PD‐1 knockout EBV‐CTL | Single Group | 20 | Stage IV EBV positive malignancies | II | NCT03044743 | Mar 2022 |
| TGF‐beta‐resistant cytotoxic T cells | Single Group | 14 | Recurrent/refractory EBV positive NPC | I | NCT02065362 | Feb 2033 |
| LMP, BARF‐1, and EBNA1‐specific CTLs (MABEL CTLs) | Parallel, Nonrandomized | 42 | EBV positive tumor | I | NCT02287311 | Mar 2025 |